Wrong. Curing spinal cord injuries is vastly more complicated than halting macular degeneration. And takes far more time to see results. Plus eye is immuno-privileged site (doesn't reject and require immuno-suppressants). Furthermore, the number of people suffering from macular-degeneration is huge, whereas those with spinal cord injuries make up a very small pool of patients.
Stem cells were only the wrong path for Gern, in particular, (to survive at this time in their development). They had to choose one focus that would give them the fastest results. But it is NOT a "wrong path" for ACTC! For ACTC it is totally the *RIGHT* path and is going to succeed beyond anyone's wildest dreams! Not only with eye disease cures. Also heart, blood and much more.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.